ヒト肝臓モデルの世界市場 - 世界の産業規模、シェア、動向、機会、予測、2018年～2028年、製品別（2Dモデル、3Dバイオプリンティング、肝臓オルガノイド）、用途別（創薬、学術・研究）、地域別、競合別

世界のヒト肝臓モデル市場は、2022年に5億6,745万米ドルと評価され、2028年までのCAGRは4.17%で、予測期間中に目覚ましい成長を予測しています。

ヒト肝臓モデルの世界市場とは、特に医薬品開発や毒性試験などの様々な用途において、ヒト肝臓の構造や機能を模倣するように設計された革新的で高度なシステム、技術、モデルの市場を指します。これらの肝臓モデルは、製薬研究における貴重なツールとして機能し、研究者や組織による肝臓関連疾患の研究、新薬の安全性と有効性の試験、動物実験の必要性の低減を可能にします。

市場促進要因

医薬品研究の進歩

世界のヒト肝臓モデル市場は、製薬研究の急速な進歩が大きな原動力となって、一変した需要の急増を経験しています。製薬業界は、時間とコストを削減しながら、より安全で効果的な医薬品を開発しなければならないというプレッシャーに直面しており、ヒト肝臓モデルは不可欠なツールとして浮上しています。

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界のヒト肝臓モデル市場の展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • 製品別（2Dモデル、3Dバイオプリンティング、肝臓オルガノイド）
  • 用途別（創薬、学術・研究）
  • 地域別
  • 企業別（2022年）
• 製品市場マップ
  • 製品別
  • 用途別
  • 地域別

第6章 北米のヒト肝臓モデル市場の展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • 製品別
  • 用途別
  • 国別
• 北米：国別分析
  • 米国
  • カナダ
  • メキシコ

第7章 欧州のヒト肝臓モデル市場の展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • 製品別
  • 用途別
  • 国別
• 欧州：国別分析
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン

第8章 アジア太平洋のヒト肝臓モデル市場の展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • 製品別
  • 用途別
  • 国別
• アジア太平洋：国別分析
  • 中国
  • 日本
  • インド
  • オーストラリア
  • 韓国

第9章 南米のヒト肝臓モデル市場の展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • 製品別
  • 用途別
  • 国別
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカのヒト肝臓モデル市場の展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • 製品別
  • 用途別
  • 国別
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 最近の展開
• 合併・買収
• 製品発表

第13章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第14章 競合情勢

• 事業概要
• 提供製品
• 近年の発展
• 財務
• 主要人材
• SWOT分析
  • Organovo Holdings Inc
  • BioIVT LLC
  • InSphero AG
  • Emulate Inc
  • Mimetas BV
  • CN Bio
  • Cyfuse Biomedical KK
  • Hurel Corp

第15章 戦略的提言

第16章 調査会社について・免責事項

Global Human Liver Model Market has valued at USD 567.45 million in 2022 and is anticipated to project impressive growth in the forecast period with a CAGR of 4.17% through 2028. The Global Human Liver Model Market refers to the market for innovative and advanced systems, technologies, and models designed to mimic the structure and functions of the human liver for various applications, particularly in drug development and toxicology testing. These liver models serve as valuable tools in pharmaceutical research, enabling researchers and organizations to study liver-related diseases, test the safety and efficacy of new drugs, and reduce the need for animal testing.

Key Market Drivers

Pharmaceutical Research Advancements

The Global Human Liver Model Market is experiencing a transformative surge in demand, driven in large part by the rapid advancements in pharmaceutical research. As the pharmaceutical industry faces increasing pressure to develop safer and more effective drugs while reducing time and costs, human liver models have emerged as indispensable tools.

Pharmaceutical companies are continually searching for more efficient and accurate ways to evaluate drug candidates. Human liver models provide a realistic and dynamic environment to test potential drugs, predict their pharmacokinetics, and assess their toxicity. This level of precision significantly reduces the risk of late-stage clinical trial failures, leading to substantial cost savings and a more streamlined drug development process.

The pharmaceutical landscape is shifting towards personalized medicine, where treatments are tailored to individual patients based on their genetic makeup and unique disease profiles. Human liver models play a pivotal role in this paradigm by allowing researchers to test drug responses on patient-derived liver tissue. Advancements in this area are driving demand for more advanced liver models, leading to innovations and market growth.

Regulatory bodies like the FDA are increasingly emphasizing the need for human-relevant data in drug development and safety assessments. Human liver models, with their ability to mimic human liver functions accurately, are becoming a preferred choice for preclinical studies. As regulatory guidelines evolve to reflect this trend, pharmaceutical companies are investing in these models to ensure compliance and streamline the drug approval process.

Recent global health crises, such as the COVID-19 pandemic, have underscored the urgency of rapid drug development. Human liver models have played a crucial role in studying the impact of viruses on the liver and screening potential treatments. These models enable scientists to expedite research during health emergencies, increasing their importance in the pharmaceutical research landscape.

Ethical concerns and a desire for more humane research practices have led to a push for reduced animal testing. Human liver models provide a viable alternative that allows researchers to obtain human-specific data without harming animals. Pharmaceutical companies are increasingly adopting these models as part of their commitment to ethical research and to meet changing regulatory requirements.

Collaboration between pharmaceutical companies, academic institutions, and technology firms is driving innovation in human liver models. Partnerships leverage collective expertise and resources to develop more advanced and scalable models. These collaborative efforts have the potential to accelerate the growth of the human liver model market.

Ethical Concerns and Regulatory Pressures

The Global Human Liver Model Market is undergoing a significant transformation, driven not only by scientific advancements but also by profound ethical concerns and regulatory pressures. In an era where ethical considerations are increasingly intertwined with scientific progress, human liver models have emerged as ethical alternatives that align with evolving regulations.

Ethical considerations have become central to the practice of scientific research. Concerns about the welfare of animals and the moral implications of animal testing have led to a reevaluation of research methodologies. Human liver models offer a humane and ethical solution, allowing researchers to obtain human-relevant data without subjecting animals to experimentation.

The pharmaceutical industry, which relies heavily on preclinical testing, is increasingly recognizing the importance of ethical research practices. Pharmaceutical companies are under pressure to demonstrate their commitment to ethical research and sustainability, and the adoption of human liver models is viewed as a responsible choice. This alignment is driving demand for liver models in drug development.

Regulatory agencies worldwide, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), have started to emphasize the importance of ethical research practices. These agencies are encouraging the use of alternatives to animal testing, which includes human liver models, to gather data that is more relevant to human responses.

Ethical concerns extend to the reduction of animal testing in research. Human liver models are a key part of this reduction strategy. They provide a way to conduct preclinical testing without the ethical dilemmas associated with animal experiments. Regulatory bodies are actively promoting this transition, pushing pharmaceutical companies to explore alternative methods.

Regulatory requirements are evolving to accommodate the use of human liver models in preclinical testing. For instance, the FDA has issued guidelines that emphasize the importance of obtaining human-specific data early in the drug development process. Meeting these changing regulatory requirements necessitates the adoption of advanced human liver models.

Ethical concerns are not limited to the scientific community but extend to the general public. Consumers are increasingly conscious of the ethical implications of the products they use, including medications. This awareness has created a demand for pharmaceutical companies to prioritize ethical research practices and consider alternatives to animal testing.

Rising Incidence of Liver Diseases

The Global Human Liver Model Market is witnessing an upsurge in demand, driven by a concerning global trend - the increasing incidence of liver diseases. As liver-related disorders continue to pose significant health challenges worldwide, human liver models are emerging as indispensable tools for research, drug development, and personalized medicine.

Liver diseases, including hepatitis, cirrhosis, non-alcoholic fatty liver disease (NAFLD), and liver cancer, have become a growing public health concern. Factors such as unhealthy lifestyles, alcohol abuse, viral infections, and obesity contribute to the rising incidence of liver diseases globally.

As the prevalence of liver diseases increases, there is an urgent need for more effective therapies and treatments. Traditional drug development processes often face challenges in predicting how drugs will affect the human liver. Human liver models offer a lifelike environment to study disease progression and test potential treatments, making them invaluable in the quest for better therapies.

The era of personalized medicine is revolutionizing healthcare. Human liver models enable researchers to study how individual patients may respond to specific drugs. By using patient-derived liver tissue in these models, treatments can be tailored to the patient's unique genetic makeup and disease characteristics.

Liver diseases impose a significant economic and healthcare burden globally. By advancing our understanding of these diseases and developing more effective treatments, human liver models can contribute to reducing the societal and economic costs associated with liver-related disorders.

Human liver models are invaluable for researching the mechanisms of liver diseases. They provide a platform to study disease progression at the cellular level and identify early biomarkers of liver diseases, potentially enabling earlier diagnosis and intervention.

Drug discovery and development are resource-intensive processes. Human liver models allow pharmaceutical companies to screen potential therapeutics more efficiently, reducing the likelihood of late-stage drug failures. This streamlining of drug development processes is driving demand for liver models in the pharmaceutical industry.

Technological Advancements

The Global Human Liver Model Market is currently undergoing a remarkable transformation, largely fueled by rapid technological advancements. These innovations are revolutionizing the field of liver research, drug development, and personalized medicine.

Technological advancements in 3D bioprinting and tissue engineering have transformed the landscape of human liver models. Researchers can now create highly intricate and physiologically accurate liver tissues that closely resemble the real organ. This innovation has significantly enhanced the relevance and reliability of human liver models in drug testing and disease research.

Organ-on-a-chip technology has emerged as a game-changer in the field of liver modeling. These microfluidic devices replicate the physiological conditions of the liver, enabling real-time monitoring and analysis of liver functions. The precision and scalability of organ-on-a-chip systems have opened up new avenues for liver research and drug testing.

Microfabrication techniques have enabled the development of miniaturized liver models with precise control over cell placement and architecture. These models allow for high-throughput screening of drug candidates and provide valuable insights into liver diseases' mechanisms.

Advances in technology have made it possible to create multi-organ systems that mimic the interactions between the liver and other organs in the body. These systems provide a more holistic understanding of how drugs and diseases affect the entire human body, promoting a more accurate evaluation of drug candidates' safety and efficacy.

Cutting-edge imaging techniques, such as high-resolution microscopy and advanced analytical tools, enable researchers to closely monitor and analyze liver models' behavior. This detailed insight into cellular and molecular processes enhances our understanding of liver function and disease progression.

AI and machine learning algorithms are being integrated into liver modeling to analyze vast datasets generated by advanced technologies. These AI-driven approaches help in predicting drug responses, identifying potential biomarkers, and optimizing experimental conditions, ultimately accelerating research and development.

Technological advancements have contributed to the improved reproducibility and scalability of human liver models. This makes it easier for researchers and pharmaceutical companies to conduct large-scale experiments and increase the efficiency of drug screening processes.

Key Market Challenges

Complexity of Liver Functionality

The liver is an incredibly complex organ with numerous functions, including detoxification, metabolism, and protein synthesis. Replicating all of its functions accurately in a model is challenging. Researchers are working on improving the physiological relevance of liver models, but achieving a complete emulation remains a formidable task.

Long-term Viability

Maintaining the viability and functionality of human liver models over an extended period is a challenge. Cells in these models can deteriorate over time, affecting the reliability of experimental results. Researchers are exploring strategies such as bioprinting and organ-on-a-chip technology to address this issue.

Interactions with Other Organs

While single liver models provide valuable insights, understanding how the liver interacts with other organs is crucial for comprehensive research. Developing multi-organ systems that replicate these interactions accurately is a challenge that researchers are actively addressing.

Key Market Trends

Multi-Organ-on-a-Chip Systems

The development of multi-organ-on-a-chip systems is a groundbreaking trend. These platforms enable the study of interactions between the liver and other organs, providing a more comprehensive understanding of how drugs and diseases affect the entire human body. Such models hold immense promise for advancing drug development and personalized medicine.

Advanced Tissue Engineering and 3D Bioprinting

Tissue engineering and 3D bioprinting technologies are evolving rapidly. These innovations allow for the creation of highly complex and physiologically accurate liver tissues that closely mimic the real organ. The increased sophistication of liver models enhances their relevance and reliability in drug testing.

Microfluidic and Lab-on-a-Chip Devices

Microfluidic and lab-on-a-chip devices are becoming more sophisticated, enabling precise control of experimental conditions. These platforms offer real-time monitoring and analysis of liver functions, providing valuable insights into drug responses and disease mechanisms.

Segmental Insights

Product Insights

Based on the category of Product, 2D Models are poised to maintain their dominance in the Global Human Liver Model Market for several compelling reasons. Firstly, they offer cost-effective and efficient solutions for studying liver-related diseases and drug testing, making them an attractive choice for both research institutions and pharmaceutical companies. Moreover, 2D Models have been widely adopted and validated over the years, establishing a robust foundation for continued use. Their simplicity and ease of use also contribute to their enduring popularity. Furthermore, as advancements in cell culture techniques and assay development continue to enhance the relevance and accuracy of 2D Models, they are likely to remain the go-to choose for liver research. In the coming years, the growing demand for liver-related studies and the practical advantages of 2D Models are expected to cement their dominant position in the market.

Application Insights

Based on Application, Drug discovery is poised to continue dominating the Global Human Liver Model Market for several compelling reasons. First and foremost, the pharmaceutical industry's unceasing quest for innovative and effective therapies drives a constant demand for reliable liver models to assess drug candidates. Human liver models play an irreplaceable role in early-stage drug testing, enabling researchers to evaluate drug metabolism, toxicity, and efficacy accurately. Moreover, the increasing complexity of drug targets and the push towards personalized medicine necessitate more sophisticated liver models, positioning drug discovery as a key driver of innovation in this market. With ongoing advancements in tissue engineering and biotechnology, drug discovery will likely maintain its dominance in the coming years, ensuring that the Global Human Liver Model Market continues to thrive.

Regional Insights

In 2022, it is foreseen that North America and Europe will claim the lion's share of the market, primarily attributable to their growing investments in research and development, advancements in organ models, and the acceptance of innovative therapeutic possibilities in these regions. Additionally, the rising incidence of liver diseases, coupled with the presence of major market players, is expected to propel market expansion during the projected period. Furthermore, the Asia Pacific region is set to increase its market share due to escalating research and development investments in emerging nations within the region. Furthermore, the ongoing development of healthcare infrastructure and a heightened focus by companies on the creation of novel therapeutics are poised to fortify regional growth.

Key Market Players

• Organovo Holdings Inc

• BioIVT LLC

• InSphero AG

• Emulate Inc

• Mimetas BV

• CN Bio

• Cyfuse Biomedical KK

• Hurel Corp

Report Scope:

In this report, the Global Human Liver Model Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Human Liver Model Market, By Product:

• 2D Models
• 3D Bio Printing
• Liver Organoids

Human Liver Model Market, By Application:

• Drug Discovery
• Academics & Research

Human Liver Model Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• Germany
• United Kingdom
• France
• Italy
• Spain
• Asia-Pacific
• China
• Japan
• India
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE
• Kuwait

Competitive Landscape

• Company Profiles: Detailed analysis of the major companies present in the Global Human Liver Model Market.

Available Customizations:

• Global Human Liver Model market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Human Liver Model Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (2D Models, 3D Bio Printing, Liver Organoids)
  • 5.2.2. By Application (Drug Discovery, Academics & Research)
  • 5.2.3. By Region
  • 5.2.4. By Company (2022)
• 5.3. Product Market Map
  • 5.3.1. By Product
  • 5.3.2. By Application
  • 5.3.3. By Region

6. North America Human Liver Model Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product (2D Models, 3D Bio Printing, Liver Organoids)
  • 6.2.2. By Application (Drug Discovery, Academics & Research)
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Human Liver Model Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Application
  • 6.3.2. Canada Human Liver Model Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Application
  • 6.3.3. Mexico Human Liver Model Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Application

7. Europe Human Liver Model Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product (2D Models, 3D Bio Printing, Liver Organoids)
  • 7.2.2. By Application (Drug Discovery, Academics & Research)
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Human Liver Model Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Application
  • 7.3.2. United Kingdom Human Liver Model Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Application
  • 7.3.3. France Human Liver Model Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Application
  • 7.3.4. Italy Human Liver Model Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Application
  • 7.3.5. Spain Human Liver Model Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Application

8. Asia-Pacific Human Liver Model Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product (2D Models, 3D Bio Printing, Liver Organoids)
  • 8.2.2. By Application (Drug Discovery, Academics & Research)
  • 8.2.3. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Human Liver Model Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Application
  • 8.3.2. Japan Human Liver Model Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Application
  • 8.3.3. India Human Liver Model Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Application
  • 8.3.4. Australia Human Liver Model Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Application
  • 8.3.5. South Korea Human Liver Model Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Application

9. South America Human Liver Model Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product (2D Models, 3D Bio Printing, Liver Organoids)
  • 9.2.2. By Application (Drug Discovery, Academics & Research)
  • 9.2.3. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Human Liver Model Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Application
  • 9.3.2. Argentina Human Liver Model Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Application
  • 9.3.3. Colombia Human Liver Model Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Application

10. Middle East and Africa Human Liver Model Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product (2D Models, 3D Bio Printing, Liver Organoids)
  • 10.2.2. By Application (Drug Discovery, Academics & Research)
  • 10.2.3. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Human Liver Model Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Application
  • 10.3.2. Saudi Arabia Human Liver Model Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Application
  • 10.3.3. UAE Human Liver Model Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Application
  • 10.3.4. Kuwait Human Liver Model Market Outlook
    • 10.3.4.1. Market Size & Forecast
      • 10.3.4.1.1. By Value
    • 10.3.4.2. Market Share & Forecast
      • 10.3.4.2.1. By Product
      • 10.3.4.2.2. By Application

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Development
• 12.2. Mergers & Acquisitions
• 12.3. Product Launches

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Products

14. Competitive Landscape

• 14.1. Business Overview
• 14.2. Product Offerings
• 14.3. Recent Developments
• 14.4. Financials (As Reported)
• 14.5. Key Personnel
• 14.6. SWOT Analysis
  • 14.6.1. Organovo Holdings Inc
  • 14.6.2. BioIVT LLC
  • 14.6.3. InSphero AG
  • 14.6.4. Emulate Inc
  • 14.6.5. Mimetas BV
  • 14.6.6. CN Bio
  • 14.6.7. Cyfuse Biomedical KK
  • 14.6.8. Hurel Corp

15. Strategic Recommendations

16. About Us & Disclaimer